Phase II Trial of SarCNU in Malignant Glioma: Unexpected Pulmonary Toxicity with a Novel Nitrosourea
| Autor: | James Perry, Stan Gertler, Gregory Cairncross, Marc Webster, Elizabeth Eisenhauer, Nancy Wainman |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Oncology Canada Nitrosourea Pathology medicine.medical_specialty Pulmonary toxicity Phases of clinical research Antineoplastic Agents Astrocytoma Central Nervous System Neoplasms chemistry.chemical_compound Glioma Internal medicine medicine Humans Pharmacology (medical) Lung Aged Pharmacology Carbon Monoxide Carmustine business.industry Academies and Institutes Cancer Middle Aged medicine.disease Clinical trial chemistry Pulmonary Diffusing Capacity Female Neoplasm Recurrence Local Glioblastoma business medicine.drug |
| Zdroj: | Investigational New Drugs. 23:591-596 |
| ISSN: | 1573-0646 0167-6997 |
| Popis: | A multi-centre phase II study of SarCNU-a novel chloroethylnitrosourea (CNU)-in patients with recurrent malignant glioma to assess response rate, survival and effects of treatment.Ten patients with histologically proven malignant glioma (seven with glioblastoma multiforme (GBM) and three with anaplastic astrocytoma) received SarCNU (860 mg/m(2)) orally on days 1, 5 and 9 on a 6 week schedule.A total of ten patients were treated on protocol before accrual was suspended for a high rate of pulmonary toxicity. Of eight evaluable patients, five demonstrated at least one grade deterioration in DLCO from baseline. This necessitated premature closure of the trial. Stable disease was seen in five of seven evaluable patients (median duration 4.8 months; range 0.8-9.2) with progressive disease in the remainder.Despite promising preclinical data, SarCNU caused pulmonary toxicity in patients with recurrent malignant glioma and we plan no further studies in this indication. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink